ライフサイエンスコーパス: P-450

1 iors, which was not significantly different (P = .450).

2 e and establishment of the enzyme as a CYP74 P-450.

3 and the eukaryotic machinery of cytochromes P-450.

4 hia coli, displayed spectral properties of a P-450.

5 at metabolism was due to PHS, not cytochrome P-450.

6 mitochondrial side chain cleavage cytochrome P-450.

7 t equimolar concentrations of azole drug and P-450.

8 te of hydroxylation at 87.8 pmol/90 min/pmol P-450.

9 smallest yet observed for a human cytochrome P-450.

10 ia coli showed spectral characteristics of a P-450.

11 f aflatoxin B(1) are mediated by cytochromes P-450.

12 clusively the C(50) beta-cyclic carotenoid C.p.450.

13 umber of genes, including certain cytochrome P-450s.

14 Microsomal cytochrome P-450 1A (CYP1A) in a vertebrate model (the teleost fish

15 in two maternal metabolic genes, cytochrome P-450 1A1 (CYP1A1) MspI and epoxide hydrolase 1 (EPHX1)

16 , suppress the gene expression of cytochrome P-450 1A1 (cyp1a1).

17 The presence of P-450 1A1 and 2D1-5 was detected by reverse transcriptio

18 The induction of P-450 1A1 and 2D1-5 was quantified using competitive PCR

19 m to examine the expression and induction of P-450 1A1 and the P-450 2D subfamily.

20 glioma C6 cells demonstrated the presence of P-450 1A1 at the protein level.

21 that genetic polymorphisms in the cytochrome P-450 1A1 gene (CYP1A1) may affect the relation between

22 by PB or BA treatment, tenfold induction of P-450 1A1 mRNA after BA treatment was detected.

23 ELISAs showed that BA induces P-450 1A1 proteins 7.3-fold.

24 conflicting findings suggest that cytochrome P-450 1A2 (CYP1A2) metabolic activity may be associated

25 ADH in reconstitution assays with cytochrome P-450 1A2 and with squalene monooxygenase.

26 eract B(a)P-mediated induction of cytochrome P-450 1B1, a prototypical AhR target gene.

27 tivator-1alpha (PGC-1alpha), CAR, cytochrome P-450 2b10 (Cyp2b10), UDP-glucuronosyltransferase 1a1 (U

28 The N-terminal signal anchor of cytochrome P-450 2C1 mediates retention in the endoplasmic reticulu

29 using antibodies raised against recombinant P-450s 2C11 and 2C23 demonstrated that P-450 2C23 is the

30 ation by P-450 2C23 (57% of total products), P-450s 2C11 and 2C24 epoxidized the 11,12-olefins and 14

31 Recombinant P-450s 2C11, 2C23, and 2C24 catalyze arachidonate metabo

32 ry globulin, alpha-1 antitrypsin, cytochrome P-450 2C13, L-type 6-phosphofructo-2-kinase, mouse major

33 was the preferred target for epoxidation by P-450 2C23 (57% of total products), P-450s 2C11 and 2C24

34 inant P-450s 2C11 and 2C23 demonstrated that P-450 2C23 is the major 2C arachidonic acid epoxygenase

35 giochemical and enantiofacial selectivity of P-450 2C23 matched that of the kidney microsomal epoxyge

36 ation studies demonstrated the expression of P-450s 2C23, 2C24, and 2C11 as the predominant kidney 2C

37 enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of

38 Cytochrome P-450 2D is a subfamily of the cytochrome P-450-dependen

39 xpression and induction of P-450 1A1 and the P-450 2D subfamily.

40 Although P-450 2D1-5 do not seem to be affected by PB or BA treat

41 Thus, this novel P-450 was named P-450 2D18 according to the recommended nomenclature (2)

42 g band of the predicted size range with anti-P-450 2D6 antiserum, which was not seen in control cells

43 0 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most

44 Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2

45 Human microsomal cytochrome P-450 2E1 (CYP2E1) monooxygenates > 70 low molecular wei

46 inhibitors, only chlorzoxazone, a cytochrome P-450 2E1 (CYP2E1) substrate, showed any significant inh

47 In a recombinant cytochrome P-450 2E1 Ames bacterial mutagenicity assay, the R597M/W

48 ase (GPx), glutathione (GSH), and cytochrome P-450 2E1 expression.

49 GSH, and increased expression of cytochrome P-450 2E1, consistent with increased hepatic oxidative s

50 ocorticoids dexamethasone [strong cytochrome P-450 3A (CYP3A) inducer] or triamcinolone acetonide (we

51 cin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications tha

52 e substrates and/or inhibitors of cytochrome P-450 3A (CYP3A).

53 dy to use catalytically distinct cytochromes P-450 3A from the same species in the elucidation of str

54 Canine cytochromes P-450 3A12 and 3A26 differ by 22 out of 503 amino acid r

55 John's Wort (SJW) may induce cytochrome P-450 3A4 activity and/or P-glycoprotein expression.

56 Cytochrome P-450 3A4 cyp304 is responsible for the metabolism of ov

57 The expression of P-450 4A protein and mRNA was localized in isolated cere

58 osatetraenoic acid (20-HETE) is a cytochrome P-450 4A/4F-derived metabolite of the membrane phospholi

59 rat cerebral microvessels express cytochrome P-450 4A1, 4A2, 4A3, and 4A8 isoforms, some of which cat

60 nesyl pyrophosphate synthase, and cytochrome P-450-51, were decreased in liver by fasting and in prim

61 lished the product of fkbD as the cytochrome P-450 9-deoxo-FK506 hydroxylase, which is responsible fo

62 tivation was accompanied by loss of spectral P-450, a variable loss of heme and a variable appearance

63 homologies to other known CYP-150 cytochrome P-450 and [3Fe-4S] ferredoxin enzymes and may be respons

64 enobiotic response genes, such as cytochrome P-450 and glutathione S-transferases, potentially involv

65 by NDO is different from that by cytochrome P-450 and other monooxygenases, which oxidize styrene to

66 enzymes, such as by inhibition of cytochrome P-450 and/or by induction of phase II detoxifying enzyme

67 on and metabolism are mediated by cytochrome P-450 and/or P-glycoprotein should require close monitor

68 odes a protein with similarity to cytochrome P-450s and was able to complement mutations in either bi

69 Phase I (cytochromes P-450) and phase II (uridine diphosphate glucuronosyltra

70 l cancer, including nicotinamide, cytochrome P-450, and tyrosine metabolism.

71 eicosatrienoic acids, products of the kidney P-450 arachidonate epoxygenase, inhibit distal nephron N

72 hese responses may be mediated by cytochrome P-450 arachidonate metabolites.

73 e addition, with proteolysis occurring while P-450s are still attached to the endoplasmic reticulum.

74 ted that constitutively expressed membranous P-450s are targeted for destruction by the proteasome, i

75 ression of CYP3A or other cytochromes P-450 (P-450s) because Pgp can transport endogenous regulators

76 and code for a novel brain cytochrome P-450 (P-450) belonging to the CYP2D subfamily, and noted that

77 iazole to determine the effect of cytochrome P-450 blockade on inflammatory responses by assessing pr

78 o tightened affinity of these inhibitors for P-450 BM3 (Kd for the C12 azole decreased to 2.7 microM)

79 the inhibitors form low-spin complexes with P-450 BM3 and that their binding induces movements of th

80 All ligate the P-450 BM3 ferric heme iron, inducing a type II shift in

81 transfer and substrate binding to cytochrome P-450 BM3 from Bacillus megaterium and its constituent h

82 ytic mechanism of the fatty acid hydroxylase P-450 BM3 from Bacillus megaterium.

83 ssociation constants for binding to oxidized P-450 BM3 heme iron were determined spectrophotometrical

84 sfer from FLDR/FLD to the fatty acid oxidase P-450 BM3 support this conclusion, indicating a ping-pon

85 compounds are the most potent inhibitors of P-450 BM3 yet reported.

86 nd preferentially to different conformers of P-450 BM3.

87 ation by cytochromes P-450(cam) (CYP101) and P-450(BM3) (CYP102).

88 Induction of cytochrome P-450s by beta-naphthoflavone (BN) enhanced CCE measured

89 of hydrocarbon hydroxylation by cytochromes P-450(cam) (CYP101) and P-450(BM3) (CYP102).

90 stributed in the C-terminal region, this new P-450 cDNA clone contained a unique 5'-extension, and we

91 A-mediated signal transduction on cytochrome P-450 cholesterol monooxygenase side-chain cleaving enzy

92 holesterol to pregnenolone (i.e., cytochrome P-450 cholesterol monooxygenase side-chain cleaving enzy

93 teasomes and microsomal fractions, labilized P-450 conformations are protected from 20 S proteasome d

94 The cytochromes P-450 (P-450s) constitute an extremely large family ('superfami

95 cyclo-oxygenase, lipoxygenase or cytochrome P-450 (cP-450) metabolism.

96 of ethoxyresorufin metabolism) of cytochrome P-450 (CYP) 1A1 and/or CYP1B1.

97 Cytochrome P-450 (CYP) 1A1 plays a key role in phase I metabolism o

98 he carcinogen-activating enzymes cytochromes P-450 (CYP) 1A1, 1A2, and 1B1.

99 Cytochrome P-450 (CYP) 1B1 expression in mouse hepatoma (Hepa-1) wi

100 for selectively inhibiting human cytochrome P-450 (CYP) 2A6, the major nicotine metabolizing enzyme.

101 and nelfinavir are metabolized by cytochrome P-450 (CYP) 2B6 and CYP2C19, respectively, with some inv

102 tide for acute heart failure, and cytochrome P-450 (CYP) 2C19 genotyping for the acute coronary syndr

103 ) by omega-oxidation catalyzed by cytochrome P-450 (CYP) 4F3A.

104 tion into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect.

105 se-inducible, male-specific liver cytochrome P-450 (CYP) genes.

106 lored the effects of cytokines on cytochrome P-450 (CYP) in rat hepatocyte primary cultures.

107 Cytochrome P-450 (CYP) is involved in the activation and metabolism

108 tohepatitis (NASH) affect hepatic cytochrome P-450 (CYP) protein expression and activity, and CYP2E1

109 Cytochrome P-450 (CYP)-derived epoxyeicosatrienoic acids (EETs) pos

110 the carcinogen activating enzymes cytochrome P-450 (CYP)1A1/CYP1A2 in microsomes and intact HepG2 cel

111 cleavage reaction catalyzed by a cytochrome P(450) (CYP) expressed predominantly in the liver.

112 transactivates expression of the cytochrome P-450 CYP1A1 gene and other genes in the dioxin-inducibl

113 contrast, of eight additional cDNA-expressed P-450s (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, and 2E1) e

114 This process was specific for P-450s CYP1A2, CYP2E1, CYP3A, and CYP4A and was not demo

115 A novel cytochrome P-450 (CYP26) that catalyzes 4-hydroxylation of all-tran

116 responsive enhancer module of the cytochrome P-450 Cyp2b10 gene, contains two potential nuclear recep

117 genes include sexually dimorphic cytochrome P 450 Cyp2d9, glutathione S-transferase pi, Cyp2a, Cyp2b

118 SNPs in cytochrome P-450 (CYP2R1)(rs10741657AG), vitamin D receptor (VDR)(r

119 tif consistent with its role as a cytochrome P-450 (CyP450) enzyme and is similar to a number of mamm

120 Thromboxane synthase (TS) is a cytochrome P-450 (CYP450) enzyme catalyzing the conversion of prost

121 ity toward imipramine, whereas another brain P-450 CYP4F6-expressed COS cell lysate showed 10-hydroxy

122 Allene oxide synthase (AOS) is a cytochrome P-450 (CYP74A) that catalyzes the first step in the conv

123 ation and characterization of the cytochrome P-450 CYP82Y1, which catalyzes the 1-hydroxylation of N-

124 inductions of the prominent PAH-metabolizing P-450 cytochrome, CYP1A1.

125 ffects, as a consequence of bioactivation by P-450 cytochromes to dihydrodiol epoxides.

126 milarity to presumed heme-binding domains of P-450 cytochromes.

127 Because cytochrome P-450-dependent arachidonate metabolites participate in

128 me P-450 2D is a subfamily of the cytochrome P-450-dependent mixed function oxidase system which is w

129 ion inhibits the lipoxygenase and cytochrome P-450-dependent pathways of arachidonic acid metabolism.

130 lates the production of an anti-inflammatory P-450 eicosanoid metabolites (cis-epoxyeicosatrienoic ac

131 roid hydroxylase CYP3A4 is the most abundant P-450 enzyme in the human liver, and CYP3A enzymes metab

132 m CYP1A2 is down-regulated and inhibition of P-450 enzyme system is associated with an exacerbated in

133 suggest that the integrity of the cytochrome P-450 enzyme system plays an important role in septic in

134 n of sepsis and, if so, whether reduction of P-450 enzyme system plays an important role in the infla

135 The metabolic activity of cytochrome P-450 enzymes has been associated with an increased risk

136 stinctly different from the major cytochrome P-450 enzymes in human liver microsomes.

137 l agents that regulate or are metabolized by P-450 enzymes might be approached cautiously in the sept

138 -1,2-diolate (V-PYRRO/NO), is metabolized by P-450 enzymes to release NO in the liver, and is shown t

139 he detoxification is performed by cytochrome P-450 enzymes, many of which have broad substrate specif

140 n implicated in the regulation of cytochrome P-450 enzymes.

141 ound in chloroperoxidase, than in cytochrome P-450 enzymes.

142 cyclooxygenase, lipoxygenase, or cytochrome P-450 epoxygenase inhibitors did not reverse the inhibit

143 In contrast, the cytochrome P-450 epoxygenase inhibitors, SKF525A and metyrapone, su

144 ism through cyclooxygenase, lipoxygenase, or P-450 epoxygenase pathways can generate a variety of eic

145 noic acids (EETs) are products of cytochrome P-450 epoxygenase that possess important vasodilating an

146 ase, but not of cyclooxygenase or cytochrome P-450 epoxygenase, significantly attenuated the vasodila

147 acid arachidonate is oxidized by cytochrome P-450 epoxygenases to four epoxyeicosatrienoic acids (EE

148 sed levels of CYP3A protein as well as other P-450s examined and of the electron donor P-450 reductas

149 le mice housed in the United States, hepatic P-450 expression was unaffected by mdr1 genotype or actu

150 type Pgp as an upstream regulator of hepatic P-450 expression, and demonstrate that these pharmacolog

151 ted inactivation of the mdr1b gene increased P-450 expression, but the effect was modest compared wit

152 The cytochrome P-450 family of enzymes performs an incredibly diverse r

153 ated genes include members of the cytochrome P-450 family that are known to oxidize B[a]P to form gen

154 express CYP1B1 as the predominant cytochrome P-450 form.

155 mask the overall effect of mdr1a absence on P-450 gene expression.

156 f C/EBP beta to activate this liver-specific P-450 gene in vivo.

157 The rat CYP2D5 P-450 gene is activated in the liver during postnatal de

158 baculovirus protein p35 can be combined with P-450 gene-directed enzyme prodrug therapy to prolong lo

159 eductase gene, dnrV, and the doxA cytochrome P-450 gene.

160 ents present in steroid-inducible cytochrome P-450 genes and is expressed in tissues in which these c

161 as found between genotypes of the cytochrome P-450 genes CYP11A1 (-528[TTTTA]n) or CYP17A1 (-34T/C) o

162 The crtX gene was likely involved in C.p.450 glucosylation in Dietzia sp. CQ4.

163 owledge of the structure and function of the P-450s has been advanced by analysis of a limited number

164 Indeed, the P-450s have been described as 'the most versatile biolog

165 lectron transfer partner for the cytochromes P-450, heme oxygenase, and squalene monooxygenase and is

166 catalytic activity of microsomal cytochromes P-450 heterologously expressed in E. coli.

167 at showed a strong resemblance to cytochrome P-450 hydroxylases.

168 operoxide insertion mechanism for cytochrome P-450 hydroxylation.

169 CYP3A4 is the major human cytochrome P-450 in a superfamily of heme-thiolate proteins that ca

170 AM) is extensively metabolized by cytochrome P-450 in humans and rodents.

171 easure the low levels of message for various P-450s in brain.

172 nyl borate, indicating a role for cytochrome P-450s in CCE.

173 nd human and rat liver microsomal cytochrome P-450 induced a high spin, type I spectra, which was rev

174 EET), a proposed CIF generated by cytochrome P-450s, induced Ca(2+) entry.

175 Rat glioma C6 cells were treated with P-450 inducers phenobarbital (PB) or benzo[a]anthracene

176 monooxygenase system which can be induced by P-450 inducers.

177 Pretreatment of mice with the cytochrome P-450 inhibitor SKF-525A eliminated both cocaine hepatot

178 alpha-naphthoflavone, an AhR and cytochrome P-450 inhibitor, blocks DMBA-induced apoptosis; 3) AhR m

179 GSH), dithiothreitol (DTT) and by cytochrome P-450 inhibitors (clotrimazole and miconazole), we measu

180 General cytochrome P-450 inhibitors and cytochrome P-450 isoform-selective

181 cyclo-oxygenase, lipoxygenase, or cytochrome P-450 inhibitors and was mimicked by 5,8,11,14-eicosatet

182 ely suppressed in the presence of cytochrome P-450 inhibitors, piperonylbutoxide and carbon monoxide,

183 Significantly, the P-450 inhibitors, SKF525A and metyrapone, both prevented

184 hanism of the second oxidative cycle of this P-450 is considered.

185 than wild-type animals, indicating that this P-450 is the principal enzyme responsible for the metabo

186 A remarkable feature of the P-450s is the manipulation of the same basic structure a

187 lase is a unique, highly specific cytochrome P-450 isoenzyme, whose expression is regulated by its na

188 ifferential inhibition of hepatic cytochrome P-450 isoenzymes, affect CY metabolism and conditioning-

189 The major hepatic P-450 isoform CYP1A2 is down-regulated and inhibition of

190 his study was to determine whether the major P-450 isoform in rat liver (i.e., CYP1A2) is down-regula

191 CYP1A2 is a major cytochrome P-450 isoform in the liver and the olfactory mucosa but

192 epoxygenase in the rat kidney and the renal P-450 isoform regulated by excess dietary salt intake.

193 l cytochrome P-450 inhibitors and cytochrome P-450 isoform-selective substrates and inhibitors were u

194 Of a panel of 30 human cytochrome P-450 isoform-selective substrates and inhibitors, only

195 ltered following endotoxin shock, changes in P-450 isoforms in sepsis have not been fully investigate

196 P-450 isoforms in the liver (i.e., CYP1A2 and 4A1) were

197 roRNAs (miRNAs) that regulate the cytochrome P-450 isoforms involved in acetaminophen (APAP) toxicity

198 In an additional experiment, all P-450 isoforms were inhibited by pretreatment with 1-ami

199 e first report that associates an individual P-450 isozyme in brain with a particular metabolic alter

200 Cytochrome P-450 isozymes were induced in C57 bl/6 mice by either b

201 Classical cytochrome P-450 ligands such as the mechanism-based inactivator 1-

202 , revealed the presence of a gene encoding a P-450-like enzyme with a deduced Mr of 46,096.

203 treptomyces sp. strain C5 doxA, a cytochrome P-450-like protein, to be daunorubicin C-14 hydroxylase.

204 5 pmol/min/mg, 25-fold less than the rate of P-450 loss.

205 interactions (because both share cytochrome P-450 metabolic pathways).

206 model suggests that both CIF from cytochrome P-450 metabolism and secretion-like coupling mechanisms

207 -derived vasodilators formed from cytochrome P-450 metabolism of arachidonic acid.

208 potent vasodilators derived from cytochrome P-450 metabolism of arachidonic acid.

209 targeting reduced lipophilicity to attenuate P-450 metabolism revealed that incorporation of a cyclop

210 ion of 8,9- or 11, 12-EET indicating further P-450 metabolism was not required.

211 ypertension would be prevented if cytochrome P-450 metabolism were inhibited by cobalt chloride (CoCl

212 rapy, but their susceptibility to cytochrome P(450) metabolism reduces their systemic availability an

213 s further support the notion that cytochrome P-450 metabolites may be CIFs.

214 The effectiveness of the four cytochrome P-450 metabolites of arachidonic acid on recovery of Ca2

215 EDHF candidates include cytochrome P-450 metabolites of arachidonic acid, K(+), hydrogen pe

216 one) and the C(50) beta-cyclic carotenoid (C.p.450 monoglucoside).

217 arachidonic acid (AA), formed by cytochrome P-450 monooxygenase (P450), are endothelium-derived hype

218 The cytochrome P-450 monooxygenase 3A4 (CYP3A4) is responsible for the

219 tcL gene is predicted to encode a cytochrome P-450 monooxygenase and is located within a cluster of o

220 entified in plants and fungi as a cytochrome P-450 monooxygenase evolved from the first eukaryotic cy

221 DoxA is a cytochrome P-450 monooxygenase involved in the late stages of dauno

222 oic acids (EETs), products of the cytochrome P-450 monooxygenase metabolism of arachidonic acid, can

223 y, we believe the presence of the cytochrome P-450 monooxygenase system in glial cells of the brain m

224 a C6 cell line contains an active cytochrome P-450 monooxygenase system which can be induced by P-450

225 soluble methane monooxygenase and cytochrome P-450 monooxygenase, which produce chloral hydrate.

226 Renal microsomal cytochrome P-450 monooxygenase-dependent metabolism of arachidonic

227 The cytochrome P-450 (P-450) monooxygenase system can catalyze the oxidation o

228 These include two cytochrome P-450 monooxygenases (P450s), designated RapJ and RapN,

229 c acids (EETs) are synthesized by cytochrome P-450 monooxygenases and released into the blood.

230 P to 2'-F-ara-ddA was mediated by microsomal P-450 NADPH reductase system, as shown by the liver micr

231 on the properties of this second microsomal P-450 of vegetatively growing yeast.

232 dox active transition metal ions, cytochrome p-450, or hydroperoxide lyase.

233 ocess we demonstrate is mediated by a single P-450, OrdA, in Aspergillus parasiticus in accord with f

234 sterols at the C-22 position, no cytochrome P-450 orthologs are present in the genome.

235 henoxyl radicals with human NADPH-cytochrome P-450 oxidoreductase (OR) and NADPH.

236 frames and code for a novel brain cytochrome P-450 (P-450) belonging to the CYP2D subfamily, and note

237 The cytochrome P-450 (P-450) monooxygenase system can catalyze the oxid

238 tic expression of CYP3A or other cytochromes P-450 (P-450s) because Pgp can transport endogenous regu

239 The cytochromes P-450 (P-450s) constitute an extremely large family ('su

240 zo[a,l]pyrene (DB[a,l]P) by human cytochrome P-450 (P450) 1A1 and 1B1 was investigated in Chinese ham

241 A human cytochrome P-450 (P450) 1B1 cDNA was expressed in Saccharomyces cer

242 cyclophosphamide (CPA)-activating cytochrome P-450 (P450) gene provides the capacity for localized pr

243 duced by either a lipoxygenase or cytochrome P-450 pathway, to act as a potent indirect modulator of

244 catalytic cycles of heme-containing enzymes (P-450s, peroxidases, catalases, and cytochrome c oxidase

245 The cytochrome P-450 PikC from Streptomyces venezuelae exhibits signifi

246 Recent studies using the cytochrome P-450 prodrug cyclophosphamide exemplify how the antiapo

247 Although hepatic cytochrome P-450 protein concentrations are altered following endot

248 eduction of DZQ and AZQ by NADPH: cytochrome P-450 reductase at physiological pH therefore affords th

249 NADPH-cytochrome P-450 reductase is the electron transfer partner for the

250 P-450 reductase shows very high selectivity for NADPH an

251 de adenine dinucleotide phosphate:cytochrome P-450 reductase); 3) changes in molecules involved in DN

252 d to the flavin-containing enzyme cytochrome P-450 reductase, both semiquinone and superoxide (O(2)(*

253 ctivities in an NADPH- and NADPH: cytochrome P-450 reductase-dependent manner.

254 one similar to that observed with cytochrome P-450 reductase.

255 s approximately 100-fold slower than that of P-450 reductase.

256 er P-450s examined and of the electron donor P-450 reductase.

257 esser degree, with those of NADPH-cytochrome P-450 reductase.

258 ucing systems ascorbate (Asc) and cytochrome P(450) reductase (CPR), measure rate constants of Cygb r

259 Purified NADPH:cytochrome c (P-450) reductase (FpT; NADPH-ferrihemoprotein oxidoreduc

260 ion of DT-diaphorase and NADPH:cytochrome c (P-450) reductase, two enzymes known to activate MC, rest

261 ]methoxychlor (7.2 and 14.6 pmol/90 min/pmol P-450, respectively), indicating that these isoforms do

262 Cytochrome P-45061 (CYP61) was a cytochrome P-450 revealed during the yeast genome project when chro

263 in COS1 cells of chimeric proteins with the P-450 signal anchor in an internal or C-terminal positio

264 ant domain contains the catalytic cytochrome P-450 site for arginine oxidation by molecular oxygen as

265 sterone to [3H]aldosterone (i.e., cytochrome P-450 steroid 11 beta-monooxygenase/aldosterone synthase

266 or-1 (SF-1) regulatory element of cytochrome P-450 steroid hydroxylase genes.

267 nt regulator of the expression of cytochrome P-450 steroidogenic enzymes in cultured cells.

268 Four P-450 structures have been solved to date, all of which

269 ubstrates specific for 10 distinct mammalian P-450 subfamilies did not compete with all-trans RA for

270 d sequence defines a previously unidentified P-450 subfamily (CYP74D).

271 ompiled a database of known human cytochrome P-450 substrates, products, and nonsubstrates for 38 enz

272 d oxidase components of bacterial cytochrome P-450 systems, which allow catabolism or anabolism of un

273 tent cholinesterase inhibitors by cytochrome P-450 systems.

274 CYP2El, a cytochrome P-450 that is well conserved across mammalian species, m

275 g monooxygenase and by analogy to cytochrome P-450, the accumulation of a reduced and activated oxyge

276 um poppy chemotypes revealed four cytochrome P-450s, three from the CYP82 and one from the CYP719 fam

277 eroxides are metabolized by CYP74 cytochrome P-450s to various oxylipins that play important roles in

278 ein phosphatase 2C (ToPP2C-1) and cytochrome P-450 (ToCYP-1) protein from dandelion.

279 virH operon contains two genes that resemble P-450-type monooxygenases.

280 Thus, this novel P-450 was named P-450 2D18 according to the recommended

281 e reminiscent of the mechanism of cytochrome P-450, where a heme iron stabilizes the activated O2 spe

282 sess current knowledge of the many bacterial P-450s, with emphasis on their diverse biological roles

283 Much research is focussed on mammalian P-450s, with their roles in such processes as steroid tr